Introduction
Erectile dysfunction (ED) is a common, multifactorial condition in men that is associated with increasing age and comorbid conditions such as diabetes, cardiovascular disease, and depression.
1,2 Additionally, differences in ethnicity, culture, socioeconomics, and psychosocial issues may influence whether a patient acknowledges he has ED, seeks treatment for ED and the comorbid conditions, or responds to prescribed treatments. Factors such as genetics often predispose patients to certain comorbidities and may influence the response to treatment. For example, Black Americans have a higher prevalence of diabetes mellitus and hypertension than Caucasians and Hispanics have a higher prevalence of hypertension and factors linked to cardiovascular disease than non-Hispanic men. [3] [4] [5] [6] Clinical trials conducted with the phosphodiesterase type 5 (PDE5) inhibitors have shown that these drugs are efficacious and well tolerated for the treatment of ED. [7] [8] [9] In the phase 3, placebo-controlled clinical studies with tadalafil, a majority of the patients were Caucasian, even though ethnicity was not an exclusion criterion. 10 In addition, a significant proportion of these patients were p65 years of age, and free of diabetes mellitus (diabetes) or depression. Age, diabetes, and depression are strong risk factors associated with ED. 11, 12 In order to determine the impact of ethnicity on patient response to tadalafil, a noninferiority study design was used to assess efficacy of tadalafil in Black American and Hispanic men with ED compared with Caucasian patients.
Materials and methods

Study design
Multiple observations in men with ED in national tadalafil study (MOMENTUS) was a multicenter, open-label study conducted in the US to evaluate the efficacy and safety of tadalafil 20 mg taken by various populations of men with ED. This study included a unique noninferiority design 13 to compare efficacy of tadalafil in Black American and Hispanic men with ED to a Reference group comprised of Caucasian patients with similar characteristics to those of a significant portion of patients in pivotal trials of tadalafil.
MOMENTUS had a 4-week, treatment-free, run-in period followed by 12 weeks of treatment with tadalafil taken on an as-needed basis before potential sexual activity with a maximum of one dose per day. Patients were free to choose the time between dose administration and sexual intercourse attempt. Dosing instructions included expected duration of efficacy of tadalafil up to 36 h postdosing and there were no restrictions on food intake relative to dosing.
Patient population
All study participants were male patients 18 years of age or older with at least a 3 month history of ED. Patients were asked to respond to the efficacy questions based on their interactions with the same adult female sexual partner. The study participants were advised not to use any other ED treatment for 4 weeks before receiving the initial dose of study medication (run-in phase), during the treatment phase of the study, and for 96 h after the final study visit.
Patients were placed into one of eight groups based on demographic characteristics and comorbid conditions ( Table 1 ). The focus of this analysis is patients in Groups 1-3 who were grouped by ethnicity. The analyses of the remaining five groups will be presented in separate manuscripts.
Group 1 comprised Caucasian men, p65 years of age, without a diagnosis of diabetes mellitus or depression. This group was designated the Reference group because their demographic characteristics closely matched those of a significant proportion of patients in phase 3 efficacy and safety clinical trials with tadalafil. 7 Group 2 included Black American men who were p65 years of age and without a diagnosis of diabetes mellitus or depression. Group 3 comprised Hispanic men who were p65 years of age and without a diagnosis of diabetes mellitus or depression.
Exclusion criteria for the study included (1) certain cardiovascular conditions such as recent history of a stroke or myocardial infarction, unstable angina; (2) treatment with nitrates, cancer chemotherapy, or antiandrogens; (3) failure to achieve any erection following radical prostatectomy or pelvic surgery; (4) penile implants or clinically significant penile deformities; (5) previous sildenafil citrate (sildenafil) treatment that, in the opinion of the investigator, had been ineffective; (6) ED due to other primary sexual disorders or an untreated endocrine disease.
The first patient was enrolled in the study in August 2003 and the last patient completed the study in March 2004.
Primary efficacy measures
The primary measurement of efficacy in this study was the change from baseline in the International Index of Erectile Function (IIEF) erectile function (EF) domain score for each ethnic group.
14 IIEF is a validated, multidimensional, self-administered questionnaire commonly used to assess efficacy of ED therapy. A change from baseline score of at least four points was considered clinically relevant. 15 The IIEF questionnaire was administered at the end of the run-in phase (baseline) and at the last visit.
Secondary efficacy measures
The secondary efficacy measures in this study included the sexual encounter profile (SEP) diary, The IS domain of IIEF, which comprises questions 6, 7, and 8, and the OS domain, questions 13 and 14, were used to assess the patient's satisfaction with sexual intercourse, his sexual relationship, and his sex life.
The GAQ were presented to patients at the last visit and asked whether the treatment they received improved their erections (GAQ1), and if so, whether the treatment improved their ability to engage in sexual activity (GAQ2).
The PAIRS is a self-administered questionnaire developed to evaluate psychological and relationship outcomes associated with ED and its treatment. 16 Baseline for PAIRS was determined at the end of the run-in period, and the endpoint was based on the responses at the last visit. The Sexual Self-Confidence and Spontaneity domains of PAIRS were secondary efficacy measures.
Safety
The analysis of safety included all enrolled patients. Safety was determined by all reported adverse events (AEs). Treatment-emergent adverse events (TEAEs), defined as events that first occurred or worsened after baseline, were coded according to the Medical Dictionary for Regulatory Activities (MedDRA) version 7.0 preferred terms.
Statistical analysis
Primary and secondary analyses were performed on an intent-to-treat basis and included all patients assigned to each group. Efficacy analyses included all patients with a baseline observation and at least one postbaseline observation. Baseline in this study was defined as the run-in phase. The endpoint for the study was defined as the last measurement obtained postbaseline that was on or before the final scheduled visit of the study.
The IIEF domains, SEP, and PAIRS domain responses were treated as continuous variables. The GAQ was a categorical variable and presented as counts and percentages. Paired t-test was conducted at the significance level of 0.05 to assess significance of mean change from baseline in continuous variable for each group.
The primary analysis was to determine whether efficacy of tadalafil in Black Americans and Hispanics is noninferior to Caucasians. The noninferiority analysis used an analysis of covariance (ANCOVA) model, which included terms for baseline value of the IIEF EF score, group, pooled site, age, presence of cardiovascular disease and/or hypertension, and baseline by-group interaction (if Po0.10).
There were two identical coprimary analyses in this study, one comparing the Reference group and the Black American patients and the second comparing the Reference group and the Hispanic patients. Each comparison was tested at the twosided 0.025 levels for the IIEF EF domain, allowing a final inference of both comparisons at a significance level of 0.05.
The first step in the noninferiority analyses was to confirm that the change from baseline in the IIEF EF domain score was statistically significant for Black American and Hispanic patients. The noninferiority test would then be conducted provided that patients in Groups 1-3 were appropriately balanced at baseline with respect to baseline ED severity (if comparison groups differed in percentage of patients with severe ED from the Reference group by o10%), age (if comparison groups differed in mean age from the Reference groups by o10 years), and the presence of cardiovascular disease and/or hypertension (if comparison groups differed in percentage of cardiovascular disease and/or hypertension from the Reference group by o10%).
In the next step, a confidence interval (CI) for the difference in the mean change from baseline in IIEF EF scores between the Reference group and the Black American and Hispanic groups was derived from the ANCOVA model as described above. The efficacy of tadalafil in the Black American and Hispanic groups would be noninferior to the Reference group if the lower limit of the two-sided, 97.5% CI was greater than À3.9. The clinical reference value of À3.9 was derived from statistical analyses of data from previous studies. 17 This value represents 40% of the difference in mean change from baseline in the IIEF EF domain score between patients with demographic characteristics similar to those of the Reference group who received tadalafil 20 mg and placebo in pivotal studies with tadalafil. This percentage is in accordance with the commonly accepted standard that the reference value for noninferiority be between one-third and one-half of the advantage value shown by the Reference group. [18] [19] [20] A post hoc analysis was performed to determine the proportion of patients who attempted sexual intercourse at least once during various time intervals (40-1, 41-4, 44-12, 412-24, and 424-36 h) after dosing with tadalafil over a 12-week period. The mean per-patient proportion of 'yes' responses Tadalafil is efficacious in Black American and Hispanic men with ED P Gomery et al to SEP3 was used to assess the efficacy of tadalafil at various time intervals postdosing. Additional post hoc analyses included (1) assessment of satisfaction with hardness (SEP4 ¼ yes) and overall sexual experience (SEP5 ¼ yes) for successful attempts (SEP3 ¼ yes) when patients received tadalafil and (2) the proportion of patients with baseline IIEF EF domain score o26 who achieved an EF domain score in the normal range (IIEF EF X26) at endpoint.
The safety analysis included all enrolled patients and was assessed by all reported AEs. In the analysis of TEAEs, all secondary conditions recorded at Visit 1 and any on-study AEs between Visits 1 and 2 were used as baseline. Tadalafil is efficacious in Black American and Hispanic men with ED P Gomery et al 2 ¼ 239 Black Americans, and Group 3 ¼ 199 Hispanics). The baseline demographic characteristics of the patients in these three groups are presented in Table 2 . There was a clinical difference between the Reference and Hispanic groups in the proportion of patients with severe ED, cardiovascular disease, and/or hypertension. The ANCOVA model included baseline characteristics of age, ED severity, and presence of cardiovascular disease and/or hypertension to adjust for any differences in these characteristics between the groups.
Results
Demographics
This multicenter study was conducted in the US at 187 sites and enrolled 1911 patients. Of these patients, 1641 completed the study including 989 in Groups 1-3 (Group 1 ¼ 551 Caucasians, Group
Primary efficacy measure
Tadalafil improved EF in the Reference, Black American, and Hispanic groups when measured by the change from baseline to endpoint in the IIEF EF domain score, the primary measurement of efficacy in this study. In all three groups, the IIEF EF domain score improved by at least 9.5 points, which was statistically significant (Po0.001) and clinically meaningful (Table 3) , 15 and the efficacy of tadalafil in the Black American and Hispanic groups was noninferior to the Reference group. The 97.5% CI for the difference in change from baseline in IIEF EF domain scores between the Black American group and the Reference group was (À1.88, 0.02). For the Hispanic and Reference group, the CI was (À1.74, 0.36). The lower limit of the CI in each of these analyses was greater than À3.9. The noninferiority testing demonstrated that tadalafil was as efficacious in the Black American and Hispanic groups as in the Reference group.
Secondary efficacy measures
In all three ethnic groups, the improvement from baseline in the percentage of positive responses to SEP questions 1-5 was statistically significant (Po0.001). The mean per-patient percentage of yes responses at endpoint for SEP1 (achieve erection) was X89%; SEP2 (penetrate partner), X86%; SEP3 (successful intercourse), X77%; SEP4 (satisfaction Tadalafil is efficacious in Black American and Hispanic men with ED P Gomery et al with hardness of erection), X68%; and SEP5 (OS with the sexual experience) X66% (Table 4) . In each group, X84 and X82% of successful intercourse attempts had corresponding satisfaction with the hardness of erection (SEP4) and with the sexual experience (SEP5), respectively. Patients in each group engaged in sexual activity across a broad time period up to 36 h postdosing with tadalafil. Approximately half the sexual intercourse attempts occurred between 4 and 36 h after taking tadalafil and the mean per-patient success rate (SEP3) across several time periods was high, at least 78% for the Reference and Black American groups and 80% for the Hispanic group (Figure 1) .
In each group, the IIEF EF, IS, and OS domain scores at endpoint increased significantly (Po0.001) over the baseline scores (Tables 3 and 4 ). There was a statistically significant mean change from baseline in the IIEF EF domain score (Pp0.005) for each group in each category of baseline ED severity, as measured by IIEF EF domain score (Figure 2) . The percentage of patients who achieved IIEF EF domain score in the normal range (X26) was 70% for Caucasians, 67% for Black Americans, and 68% for Hispanics.
The proportion of 'yes' responses to GAQ in the three groups was X90% for GAQ1 and X88% for GAQ2 (Table 4) .
The mean change in response from baseline to endpoint for the Sexual Self-Confidence domain of PAIRS was 1.02 for Caucasians, 0.84 for Black Americans, and 0.94 for Hispanics and statistically significant for each group (Po0.001). The mean change for the Spontaneity domain of PAIRS was 0.26 for each ethnic group and was statistically significant (Po0.001).
Safety
Tadalafil was well tolerated by patients in the Caucasian, Black American, and Hispanic groups. The TEAEs reported in at least 2% of the patients during the treatment phase of the study are listed in Table 5 . The most common TEAE reported across the three groups was headache (9.2-10.7%) and the overall discontinuation rate due to AEs was 2.3%. The percentage of patients reporting serious AEs across the three groups was low (0.8-1.7%).
Discussion
Traditional noninferiority trials can be used to demonstrate comparable efficacy between active 21 the Hispanic population in MO-MENTUS had a higher percentage of patients with mixed ED etiology than the other ethnic groups, and was younger with less severe ED, suggesting a desire to seek early treatment. A higher percentage of Black American patients in MOMENTUS had body mass index X30 kg/m 2 , were more likely to smoke, and, similar to the study with sildenafil and another study with vardenafil, had a higher occurrence of cardiovascular disease (including hypertension). 21, 22 Despite the differences in baseline characteristics, tadalafil 20 mg improved the EF of patients who were Caucasian, Black American, or Hispanic. Across all three groups, the mean change in the IIEF EF domain was statistically significant and clinically relevant. The statistical model adjusted for certain baseline characteristics and showed that the efficacy of tadalafil in the Black American and Hispanic groups was noninferior to the Reference group.
The consistency in the efficacy of tadalafil across the three groups was also shown during various time intervals postdosing and in responses to questions on patient sexual satisfaction. A high rate of successful intercourse attempts (X78%), determined by SEP3, occurred for the three groups across several time intervals up to 36 h postdosing (Figure 1) . Additionally, there were improvements from baseline in the IS and OS domains of IIEF and in the patients' psychological and relationship outcomes with a statistically significant improvement from baseline in the Sexual Self-Confidence and Spontaneity domains of PAIRS.
The noninferiority analysis shows that tadalafil is as efficacious in Black Americans and Hispanics as in Caucasians (Reference group) for the treatment of ED. Enrollment of these groups in this study was limited to patients who were p65 years of age and without comorbid diabetes and depression, a possible study limitation. Another possible limitation of this analysis is the lack of a placebo control. This noninferiority study design allowed for direct comparisons in efficacy between the Black American or Hispanic men and the Caucasian men, instead of a placebo control, and for the inference to be made that the treatment would have been more effective than placebo had the placebo control been included.
Tadalafil 20 mg was well tolerated with headache reported most frequently as a TEAE by men in all three ethnic groups.
Conclusions
This noninferiority study showed that tadalafil was as efficacious in Black American men or Hispanic men as in Caucasian men. The MOMENTUS study has established the efficacy and safety of tadalafil in various populations of men with ED 23 and confirms that when men know about the drug's 36 h duration of efficacy, they will make use of it. Determining the efficacy and safety of tadalafil in Black American and Hispanic men adds to the understanding of how the drug can be used to treat ED in men from different ethnic groups.
